The breadth of applications will widen as the number of new platforms grows, according Joshua Calvert, MD, MPH.
Joshua Calvert, MD, MPH
Advertisement
Articles by Joshua Calvert, MD, MPH
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Individualizing androgen pathway therapy in mCSPC
3
Testosterone deficiency: FAQs from the AUA guideline
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5